Realtime | Geld | Brief | Zeit |
---|---|---|---|
8,250 | 8,450 | 23:01 | |
8,250 | 8,450 | 22:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
---|---|---|---|---|
07.03. | Theravance Biopharma, Inc. - 10-K, Annual Report | - | SEC Filings | |
THERAVANCE BIOPHARMA Aktie jetzt für 0€ handeln | ||||
27.02. | Theravance's Q4 Loss In Line With Estimates, Sales Beat | 2 | Zacks | |
26.02. | Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results | 85 | PR Newswire | |
26.02. | Theravance Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | |
26.02. | Research Analysts Set Expectations for TBPH FY2028 Earnings | 2 | MarketBeat | |
25.02. | H.C. Wainwright maintains Theravance stock Buy rating, $15 target | 3 | Investing.com | |
14.11.24 | Theravance Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | |
13.11.24 | Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y | 3 | Zacks | |
12.11.24 | Theravance Biopharma GAAP EPS of -$0.26 misses by $0.03, revenue of $16.87M beats by $1.45M | 1 | Seeking Alpha | |
12.11.24 | Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value | 525 | PR Newswire | |
11.11.24 | Theravance Biopharma Q3 2024 Earnings Preview | 4 | Seeking Alpha | |
18.10.24 | Theravance study shows YUPELRI improves COPD lung function | 1 | Investing.com | |
05.08.24 | Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update | 107 | PR Newswire | |
13.05.24 | Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update | 168 | PR Newswire |